Mendus: Broadening vididencel pipeline in bloodborne tumours - Redeye

Redeye comments on Mendus announcing a clinical strategy update, communicating its aim to address broader AML and CML populations in its vididencel pipeline. Furthermore, the company announced a reorganisation to reduce costs. Overall, we appreciate vididencel’s broader focus, enlarging its market opportunity in bloodborne tumours. However, this will likely also delay potential market approval and licensing deals versus our previous estimates, likely requiring alternative financing options.

Länk till analysen i sin helhet: https://www.redeye.se/research/1129309/mendus-broadening-vididencel-pipeline-in-bloodborne-tumours?utm_source=finwire&utm_medium=RSS